We have identi®ed the physical interaction between the Breast Cancer susceptibility gene product BRCA1 and the Hereditary Non-Polyposis Colorectal Cancer (HNPCC) and DNA mismatch repair (MMR) gene product hMSH2, both in vitro and in vivo. The BRCA1-hMSH2 association involved several well-de®ned regions of both proteins which include the adenosine nucleotide binding domain of hMSH2. Moreover, the interaction of BRCA1 with puri®ed hMSH2-hMSH6 appears to be modulated by adenosine nucleotide much like G protein downstream interaction/signaling is modulated by guanosine nucleotide. BARD1, another BRCA1-interacting protein, was also found to interact with hMSH2. In addition, BRCA1 was found to associate with both hMSH3 and hMSH6, the heterodimeric partners of hMSH2. These observations implicate BRCA1/BARD1 as downstream eectors of the adenosine nucleotideactivated hMSH2-hMSH6 signaling complex, and suggest a global role for BRCA1 in DNA damage processing. The functional interaction between BRCA1 and hMSH2 may provide a partial explanation for the background of gynecological and colorectal cancer in both HNPCC and BRCA1 kindreds, respectively. Oncogene (2001) 20, 4640 ± 4649.
Introduction
BRCA1 is a tumor suppressor gene that is mutated in approximately 20 ± 45% of inherited breast cancers (Couch et al., 1997; Easton et al., 1995; Neuhausen and Marshall, 1994; Struewing et al., 1997) . While the function of BRCA1 remains enigmatic, overexpression of BRCA1 causes growth retardation in several breast or ovarian cell lines (Jensen et al., 1996) as well as apoptosis in an inducible system (Harkin et al., 1999) . BRCA1 mRNA levels are elevated at the late G1 and early S phase, suggesting a role for BRCA1 at speci®c stages of the cell cycle. Phosphorylation levels of BRCA1 also appear to be altered in a cell cycle dependent manner (Chen et al., 1996; Runer et al., 1999; Runer and Verma, 1997; Zhang et al., 1997) .
Several lines of evidence suggest that BRCA1 may participate in DNA damage assessment and/or repair: (1) BRCA1 has been found to associate with a variety of DNA repair proteins including hRad51, one of six human homologs of bacterial RecA protein (Scully et al., 1997b,c) , (2) cells derived from BRCA1 7/7 mice are de®cient in the transcription-coupled repair (TCR) of oxidative DNA damage (Gowen et al., 1998) and (3) the BRCA1 protein is hyperphosphorylated in response to DNA damaging agents and undergoes independent altered sub-nuclear localization either with the doublestrand break repair complex hRAD50-MRE11-p95 (Zhong et al., 1999) (p95 is altered in the Njimengen Breakage Syndrome and is also known as Nibrin or NBS1) or with RAD51 and the BRCA1-associated RING domain protein (BARD1) (Scully et al., 1997b, c) .
These observations are complicated by observations which suggest that BRCA1 plays a role in mediating gene transcription: (1) the C-terminal region of BRCA1 (BRCT domain) is rich in acidic amino residues and can act as a transcription factor when it is fused with the Gal4 DNA binding domain (Chapman and Verma, 1996; Monteiro et al., 1996) , (2) BRCA1 has been found to be associated with the RNA polymerase II (RNA Pol II) holoenzyme, probably through an association with RNA Helicase A (Anderson et al., 1998; Scully et al., 1997a) , and (3) BRCA1 has been shown to interact with a number of transcription factors. For example, BRCA1 appears to bind p53 and aects the transcription of p21 (Chai et al., 1999; Somasundaram et al., 1997; Zhang et al., 1998) , and it has been shown to interact with CtIP, a protein involved in gene repression Wong et al., 1998; Yu et al., 1998) . Moreover, elevated expression of BRCA1 appears to induce GADD45 as well as apoptosis in a manner that is dependent on the JNK/SAPK signaling pathway and independent of p53 (Harkin et al., 1999) , perhaps mediated by BRCA1 interaction and transcriptional inhibition of c-Myc (Amundson et al., 1998; Bush et al., 1998; Marhin et al., 1997; Wang et al., 1998) .
hMSH2 was originally identi®ed as a human homolog of the bacterial MutS protein (Fishel et al., 1993) . Mutations of hMSH2 appear to account for approximately 30 ± 40% of a common cancer susceptibility syndrome, Hereditary Non-Polyposis Colorectal Cancer (HNPCC), and have been found in a signi®cant number of sporadic cancers (Lynch et al., 1997; Peltomaki and Vasen, 1997) . hMSH2 has been shown to recognize mismatch nucleotides and other DNA lesions (Fishel et al., 1994; Mello et al., 1996) and this recognition is dramatically enhanced when paired in a heterodimeric complex with hMSH3 and hMSH6 Drummond et al., 1995 Drummond et al., , 1996 . Recent studies have demonstrated that recognition of mismatched nucleotides provokes ADP?ATP exchange by the hMSH2-hMSH3 and hMSH2-hMSH6 heterodimers, which then results in a conformational transition and the formation of a hydrolysis-independent sliding clamp thought to transduce the mismatch/ lesion signal to the repair machinery along the DNA backbone (Gradia et al., 1997 (Gradia et al., , 1999 (Gradia et al., , 2000 . The consensus Walker A/B adenine nucleotide binding (ANB) domain involved in this ADP?ATP exchange is likely to be one of the most important functional regions of hMSH2, since it accounts for 100% of the identity between the known MutS homologs (Fishel, 1998 (Fishel, , 1999 .
Here we describe the functional interaction between hMSH2 and BRCA1. Our results suggest that DNA damage processing by hMSH2 and its heterodimeric partners hMSH3 and hMSH6 results in the recruitment of BRCA1, which may subsequently play an undetermined yet fundamental role in DNA damage repair.
Results

Isolation of MSH2 as a BRCA1-interacting protein
A yeast two-hybrid screen was developed to search for proteins that interact with BRCA1. We fused the Nterminal region of human BRCA1 (aa 1 ± 303) with the Gal4 DNA binding domain to generate the`bait' construct pGalBD-nBR. Screening a`prey' HeLa cell library resulted in repeated isolation of BARD1. Because the N-terminal region of BRCA1 is largely conserved between human and mouse, we used the same bait to screen a mouse embryonic (El1) prey library (Clontech Palo Alto, CA, USA) for interaction partners. A clone that carried the carboxyl-terminal region of MSH2 (aa 888 ± 934) was isolated (designated pGAD-cMSH2), although the interaction of BRCA1 and this small fragment of murine MSH2 was weak compared to BARD1 (data not shown). This interaction was determined to be speci®c since co-transformation of pGalBD-nBR and pGAD-cMSH2 activates the HIS3 reporter, while neither plasmid alone is able to do so (data not shown).
Localization of the BRCA1-hMSH2 binding regions in vitro
To substantiate the BRCA1-hMSH2 interaction(s), we performed in vitro binding assays in which the glutathione-S-transferase (GST) fusion-protein system was used to pull down the 35 S-labeled in vitro transcribed and translated (IVTT) polypeptide, as previously described Wang et al., 1998) . The glutathione sepharose beads were loaded with similar amount of GST or GSTfusion proteins, mixed with the IVTT products, and speci®c interaction was detected by SDS ± PAGE following stringent washing. We found that the full length BRCA1 protein can bind to the GST-hMSH2 or GST-BARD1 fusion protein, but not to the GST-Max or GST protein alone ( Figure 1a ). In addition, GSThMSH3 and GST-hMSH6 were also found to interact with BRCA1 ( Figure 1b) . We noted that the interaction between BRCA1 and hMSH2, hMSH3 or hMSH6 is comparable or more intense than the BRCA1-Rad51 interaction (Figure 1b ).
BRCA1 appears to associate with GST-hMSH2 through multiple independent regions, since three non-overlapping fragments, BRCA1(1 ± 175), BRCA1(303 ± 625), and BRCA1(773 ± 1863), appear to interact with hMSH2 (Figure 1c,d; Figure 2a) . Interestingly, the point mutation C61G, in the RING ®nger domain, does not aect its association with hMSH2 suggesting that this motif is unlikely to be involved in BRCA1-hMSH2 interaction (data not shown). In addition, we found that several C-terminal deletions of BRCA1 abolish its association with hMSH2 ( Figure 1c ). Taken together with the yeast two-hybrid data, these results suggest that there are perhaps three independent hMSH2 interaction regions located in the N-terminus and C-terminus of BRCA1.
BRCA1 interacts with the adenine nucleotide-binding domain of hMSH2
The reciprocal hMSH2 interaction regions with BRCA1 were determined by a similar GST/IVTT in vitro binding assay ( Figure 2) . We have previously shown that hMSH2 interacts with both hMSH3 and hMSH6 in two distinct regions surrounding the ANB domain (aa 378 ± 625 and aa 875 ± 934) . In this study, de®ned GST-BRCA1 protein fragments were incubated with 35 S-labeled IVTT full length or partially deleted hMSH2 protein constructs. The GST-BRCA1(1 ± 175), GST-BRCA1(303 ± 625) and GST-BRCA1(773 ± 1863) fusion proteins were found to strongly and speci®cally interact with the full length hMSH2, hMSH2(609 ± 934) and hMSH2(1 ± 888), but not with hMSH2(1 ± 609) (Figure 2a,b) . These results suggest that the three regions of BRCA1 interact with hMSH2 amino acid residues 609 ± 888 (Figure 2a, b) . This region is signi®cant since it overlaps the ANB domain of hMSH2 which has been found to play an important role in transducing the mismatch/ lesion binding signal to downstream eectors such as hExoI (Fishel, 1998 (Fishel, , 1999 Schmutte et al., 1998) . In contrast to the result of the yeast two-hybrid analysis, the carboxyl-terminal region of MSH2 (aa 888 ± 934) was found to bind to the GST-BRCA1 fusion proteins very weakly (data not shown) and this region was not required for binding to BRCA1 in vitro (Figure 2 ). The discrepancy between the results of the two analyses is probably due to the fact that the yeast two-hybrid system is more sensitive in detecting weak and transient protein ± protein interactions.
BARD1 associates with hMSH2
We next investigated whether there is physical interaction between hMSH2 and BARD1, a protein known to associate with BRCA1. Using the GST-IVTT in vitro binding analysis, we found that GST-BARD1 interacted with the full length hMSH2, hMSH2(609 ± 934) and hMSH2(1 ± 888), but not with hMSH2(1 ± 609) ( Figure  3a,b) . These studies limited the BARD1-hMSH2 interaction region to hMSH2 amino acid residues 609 ± 888, coincident with BRCA1. In addition, we found modest interactions between BARD1 and hMSH3 or BARD1 and hMSH6 (data not shown). Taken together, these results support the notion that BRCA1, BARD1, or a BRCA1-BARD1 heterodimer interacts strongly with either the hMSH2-hMSH3 or the hMSH2-hMSH6 heterodimer, and that signi®cant contacts between these heterodimers exist on both complexes. Furthermore, the strongest associations appear to require the ANB domain of hMSH2 (Figure 3c ).
BRCA1 is physically associated with hMSH2 in mammalian cells
To establish that an endogenous BRCA1-hMSH2 interaction occurs within mammalian cells, we isolated nuclear extracts from human embryonic kidney 293T (HEK293T) cells and performed co-immunoprecipitation (co-IP) studies. The hMSH2 protein was eciently and speci®cally detected by Western analysis in the nuclear lysate (Figure 4a , lane 1) (Dietmaier et al., 1997; Wilson et al., 1995) . Following immunoprecipitation (IP) of the nuclear lysate with the anti-BRCA1 antibody H11D, we easily detected hMSH2 using the anti-hMSH2 antibody as a co-IP associate ( Figure 4a , lane 2). In contrast, hMSH2 was not co-precipitated from LoVo (DhMSH2) cells using the anti-hBRCA1 antibody (Figure 4a, lane 3) .
The reciprocal co-IP was performed by subjecting the nuclear lysate to IP with the anti-hMSH2 antibody and probing the blot with the BRCA1 C-20 antibody (Figure 4b) . The BRCA1 C-20 antibody is known to cross-react with EGFR or ErbB2 when whole cell lysates are used for Western Blot analysis . However, while several low . and GST-BRCA1 (773 ± 1863). The GST-BRCA1(1 ± 175), GST-BRCA1(303 ± 625) and GST-BRCA1(773 ± 1863) fusion proteins were found to strongly and speci®cally interact with the full length hMSH2, hMSH2(609 ± 934) and hMSH2(1 ± 888), but not with hMSH2(1 ± 609). Twenty-®ve per cent of each input IVTT protein was loaded in the lanes indicated as`input'. The BRCA1-interacting region (609 ± 888) overlaps the ANB domain of hMSH2. (b) Graphic representation of hMSH2 interaction with the three BRCA1 fragments molecular weight bands were detected in the nuclear lysate using the C-20 antibody in Western analysis (Wang et al., 1998) , no additional protein bands that might represent EGFR or ErbB2 were noted ( Figure  4b, lane 1) . In order to con®rm the speci®city of this endogenous interaction, we stripped the original co-IP membrane and re-probed it with another anti-BRCA1 antibody (N-20, data not shown). In both cases we observed a protein band of approximately 215 kD indicating that the BRCA1 protein is a co-IP associate of hMSH2 (Figure 4b, lane 2) . These independently correlative data strongly suggest that BRCA1 and hMSH2 form an endogenous protein complex in vivo and con®rms similar studies of the BRCA1-associated genome surveillance complex (BASC) by Wang et al. (2000) .
In order to further visualize the interaction(s) between BRCA1 and the human MutS homologs, we performed confocal microscopy immuno¯ourescent colocalization studies similar to those performed with BRCA1 and hRAD51 (Scully et al., 1997c) . We found that both hMSH2 (data not shown) and hMSH6 ( Figure 5 ) appeared to be largely co-localized with BRCA1 in nuclear foci in response to DNA damage by cis-platinum. The nuclear foci containing hMSH2-hMSH6 and BRCA1 appeared to modestly vary between cell lines and the cell cycle. Taken together 4) with the co-immunoprecipitation studies, these results strongly suggest that the cellular hMSH2 and its heterodimeric partners hMSH3 and hMSH6, form a nuclear complex with BRCA1 and perhaps other BASC proteins (Wang et al., 2000) .
Adenosine nucleotide affects the interaction between BRCA1 and hMSH2
To determine the functional signi®cance of the interaction between BRCA1 and the ANB domain of hMSH2, we examined the eect of adenosine nucleotide. These experiments are based on the observation that mismatch/lesion-containing DNA provokes AD-P?ATP exchange by hMSH2-hMSH6, which induces a conformational transition and formation of a hydrolysis-independent sliding clamp on the DNA (Gradia et al., 1997 (Gradia et al., , 1999 (Gradia et al., , 2000 . In the absence of mismatched DNA, hMSH2-hMSH6 performs a single round of ATP hydrolysis and remains bound to the ADP product, since it is refractory to ADP?ATP exchange (Gradia et al., 1997 (Gradia et al., , 1999 (Gradia et al., , 2000 . It is Figure 5 Co-localization of BRCA1 and hMSH6 in human cells. 32Dc13 cells were stained with the polyclonal anti-hMSH6 (MSH6) and monoclonal Ab-1 anti-BRCA1 (BRCA1) either untreated or treated with 10 mM of cisplatin for 3 or 6 h. DAPI staining shows the chromatin within the nucleus (DNA). Merged images (BRCA1+MSH6) from untreated (0 h) and cis-platinum treated (3 and 6 h) cells show gradual DNA damage-dependent colocalization. At 0 h, BRCA1 appears largely localized to the nuclear membrane region while hMSH6 is distributed throughout the nucleus as well as associated with the nuclear membrane region. After 6 h of treatment, BRCA1 and hMSH6 are co-localized (490% of the foci) to regions of open non-condensed chromatin, where DNA repair has been suggested to occur possible to trap the ATP-bound form of hMSH2-hMSH6 either on blocked-end mismatched DNA or in solution using the poorly hydrolyzable ATP analog, Adenosine-5'-O-(3-thiotriphosphate) (gS-ATP) (Gradia et al., 1997 (Gradia et al., , 1999 (Gradia et al., , 2000 .
We established an in vitro binding assay in which the largest speci®c N-terminal hMSH2-binding fragment of BRCA1 [GST-BRCA1(1 ± 625)] was loaded onto glutathione beads and then incubated with puri®ed hMSH2-hMSH6 in the presence of ADP, ATP, or gS-ATP (Figure 6 ) (Gradia et al., 1997 (Gradia et al., , 1999 (Gradia et al., , 2000 . The hMSH2-hMSH6 bound to GST-BRCA1(1 ± 625) was then separated by SDS ± PAGE gels and detected by Western blot using antibodies speci®c for hMSH2 and hMSH6. The introduction of ADP or ATP (which is rapidly and terminally hydrolyzed to ADP by hMSH2-hMSH6, Gradia et al., 1997 Gradia et al., , 1999 Gradia et al., , 2000 inhibited the BRCA1-hMSH2-hMSH6 interaction with an IC 50 &amp;10 mM (Figure 6a,b) . In contrast, addition of excess gS-ATP (4125 mM) did not aect the BRCA1-hMSH2-hMSH6 interaction(s) (Figure 6c) . As important controls, we have determined that gS-ATP strongly binds hMSH2-hMSH6 (k a &amp;5 mM) (Gradia et al., 2000) and the interaction between GST-BRCA1(1 ± 625) and BARD1 was not in¯uenced by adenosine nucleotide (data not shown). These observations suggest that the ADP-bound form of hMSH2-hMSH6 is incapable of binding to BRCA1 while the nucleotide-free or the stable ATP-bound form (gS-ATP) strongly interacts with BRCA1. In addition, we have found that co-precipitation of BRCA1 with hMSH2 is also modestly aected by adenosine nucleotides in the same pattern as described above, although endogenous nucleotide pools complicated an accurate assessment of these interactions in vivo ( Figure  6 ; data not shown). Finally, although both BRCA1 and BARD1 appear to associate with hMSH2 at a region that partially overlaps its association with hMSH3 or hMSH6, neither BRCA1 nor BARD1, appear to aect the mismatch binding properties of the hMSH2-hMSH3 or hMSH2-hMSH6 heterodimers (data not shown).
Discussion
An accumulating body of evidence has suggested that BRCA1 is a component of a protein complex involved in DNA damage repair and gene transcription. In the process of reviewing the manuscript of this paper, Wang et al. (2000) analysed the proteins co-immunoprecipitated with BRCA1 and identi®ed a multiprotein BRCA1-associated genome surveillance complex, BASC, which contains numerous DNA repair proteins: including hMSH2, hMSH6, hMLH1, ATM, BLM, RFC and the RAD50-MRE11-NBS1 protein complex. Our results provide further evidence that BRCA1 can associate with hMSH2-HMSH6 both in vitro and in vivo. Moreover, BRCA1 and BARD1 have been found to form an ensemble with a multi-protein transcription and repair complex that includes hRAD51 and RNA Polymerase II (Scully et al., 1997a) , which in turn is associated with TFIIB, TFIIH (which contains the Xeroderma Pigmentosum DNA repair genes XPB and XPD), TBP, XPC, XPF and XPG, DNA-PK CS , Ku70/ 86, RPA, RPC, and Pole (de Boer et al., 1998; Hanawalt, 1994; Maldonado et al., 1996; Sancar, 1994) . This complex association would appear to be signi®cant for TCR since several components of the RNA Pol II complex including BRCA1, have recognized roles in both transcription and DNA damage repair.
In addition to its role in MMR, hMSH2 has also been implicated in repair of actively transcribed genes (TCR) (Mellon et al., 1996) . Interestingly, while both hMSH2 and hMLH1 are required for TCR of UV damage Figure 6 The eects of adenine nucleotides on the interaction between BRCA1 and hMSH2. Glutathione beads loaded with GST-BRCA1(1 ± 625) were incubated with puri®ed hMSH2-hMSH6 at varying concentrations of ADP (a), ATP (b), or g-S-ATP (c). The hMSH2 and hMSH6 proteins bound to GST-BRCA1(1 ± 625) were resolved by SDS ± PAGE gel and detected by Western analysis using antibodies speci®c for hMSH2 and hMSH6. Twenty-®ve per cent of the input hMSH2-hMSH6 proteins was loaded in the lanes indicated as (In). The hMSH2-hMSH6 complex can bind to the GST-BRCA1(1 ± 625) fusion protein (lane 2). ADP caused dissociation of hMSH2-hMSH6 from BRCA1 in a dose-dependent manner (a). Similar eects were observed with ATP, probably due to the fact that ATP becomes rapidly hydrolyzed to ADP in the presence of hMSH2-hMSH6 (b). In contrast, g-S-ATP, which cannot be hydrolyzed, did not have any eect on the association between BRCA1 and hMSH2-hMSH6 (c) (Mellon et al., 1996) , only hMSH2 is required for TCR after oxidative damage (Mellon et al., 1996) . The ®nding of the BRCA1-hMSH2 interaction raises the possibility that the hMSH2-hMSH3/hMSH6 heterodimers transduce an oxidative damage (and perhaps other damage) recognition signal to BRCA1. Such a notion is substantiated by the observation that there is signi®cant functional contact between BRCA1 and BARD1 within the ANB domain of hMSH2, which appears to control the mismatch/lesion recognition signal (Fishel, 1998 (Fishel, , 1999 Gradia et al., 1997 Gradia et al., , 1999 Gradia et al., , 2000 Wilson et al., 1999) . The biological relevance of the BRCA1-hMSH2 interaction is supported by the ®nding that cells derived from BRCA1 7/7 mice are defective in TCR of oxidative DNA damage (Gowen et al., 1998) . While the disposition of a hMSH2-BRCA1 signal is unknown, it is notable that both hMSH2 and BRCA1 have been associated with apoptotic pathway(s) (Harkin et al., 1999; Zhang et al., 1999) . Thus, the available evidence can be interpreted to suggest that the BRCA1-hMSH2 complex might transduce a mispair/lesion recognition signal nonexclusively to the repair of DNA damage, cell cycle arrest and/ or apoptosis machinery. Regardless, the adenosine nucleotide modulated interaction with hMSH2-hMSH6 provides the ®rst dynamic biochemical function for BRCA1 in DNA damage processing. Because defects in the BRCA1-hMSH2 signaling process are inferred to ultimately leading to increased susceptibility to tumorigenesis, the functional connection between BRCA1 and hMSH2 may at least partially explain the high incidence of gynecological tumors in HNPCC kindreds, as well as the increased susceptibility to colon cancer in BRCA1 kindreds (Easton et al., 1995; Lynch et al., 1997) .
Materials and methods
Two hybrid analysis
The Clontech Gal4 Matchmaker yeast two-hybrid system was used. The screening procedure was performed according to the user's manual. The bait construct pGBT9-nBR contains BRCA1(1 ± 303). A mouse embryonic (E11) library was screened in yeast strain HF7c (Clontech, Palo Alto, CA, USA).
GST-IVTT protein interaction assay
The GST fusion protein constructs were made in pGEX vectors (Pharmacia). The expression of GST fusion proteins was induced by IPTG (0.1 mM) and the bacterial cells were suspended in PBS (supplemented with protease inhibitors (0.5 mM phenylmethylsulfonyl¯uoride, 0.8 mg/ml leupeptin, 0.8 mg/ml pepstatin, and 0.1 mM EDTA, and 2 mM DTT) and lysed either by sonication or by two cycles of freeze-andthaw. DNAse I (Boehringer Mannheim, Germany) was added to a ®nal concentration of 20 mg/ml and the lysate incubated on ice for 20 min in the freeze-and -thaw protocol. Triton X-100 was added to a ®nal concentration of 0.2%. After rocking at 48C for 1 ± 2 h, the glutathione beads were washed with binding buer (20 mM Tris pH 7.5, 10% glycerol, 150 mM NaCl, 5 mM EDTA, 1 mM DTT, 0.1% Tween 20, 0.75 mg/ml BSA, 0.5 mM phenylmethylsulfonyl uoride, 0.8 mg/ml leupeptin, and 0.8 mg/ml pepstatin) three times. GST-fusion protein expression levels were determined on coomassie stained SDS ± PAGE gels using BSA as a standard .
35
S-labeled protein was generated by in vitro transcription and translation (IVTT) (Promega) according to the manufacturer's recommendation. The IVTT protein (10 ml) was incubated with the GST proteins (5 mg, loaded on glutathione beads) for at least 1 h at 48C on a rocker. The glutathione beads were washed three times with the binding buer (50 mM HEPES pH 7.5, 250 mM NaCl, 0.5% NP-40, 1 mM DTT, 0.5% BSA), and then re-suspended in 50 ml of SDS loading buer (0.25 Tris pH 6.8, 5% sucrose, 2% SDS, 5% 2-mercaptoethanol, and 0.005% bromophenol blue). The samples were resolved on an SDS ± PAGE, and then imaged using a Molecular Dynamics PhosphorImager (Sunnyvale, CA, USA). Individual interaction studies were reproduced a minimum of three times with identical results.
All BRCA1, BARD1, hMSH2, hMSH3, hMSH6 and hRAD51 constructs were con®rmed by complete sequencing.
Immunoprecipitation assays
Human embryonic kidney 293T cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS). The BRCA1 antibody C-20 was purchased from Santa Cruz Biotechnology. H11D is a monoclonal antibody raised against a C-terminal fragment of BRCA1 (Wang et al., 1998) . Cell nuclei were prepared as described (Wang et al., 1998; Zhang et al., 1997) . The nuclei of 293T cells were lysed in lysis buer (150 mM NaCl, 20 mM Tris HCl (pH 8.0), 0.2 mM EDTA. 1 mM PMSF, 10% Glycerol, 1% Triton x-100) and the supernatant was subjected to immunoprecipitation with the antibody as indicated in each experiment (Wang et al., 1998) . SDS ± PAGE and Western analysis were performed as previously described (Wang et al., 1998; Zhang et al., 1997) .
Co-localization
32Dcl3 cells were grown in IMDM supplemented with 10% FBS, peni/strepto, L-glutamine and IL-3. Cells (1610 6 /ml) were untreated or treated with 10 mM cisplatin (Platinl-AQ, Bristol-Myers Squibb Co., Princeton, NJ, USA) for 3 and 6 h. BRCA1 was detected by mouse monoclonal anti-BRCA1 (Ab-1, Oncogene Research Products, Cambridge, MA, USA) followed by TRITC-conjugated goat anti-mouse Ig secondary antibody (Molecular Probes Inc., Eugene, OR, USA). MSH6 was detected by rabbit anti-MSH6 antibody (Oncogene Research Products, Cambridge, MA, USA) followed by AlexaFluor488-conjugated goat anti-rabbit Ig secondary antibody (Molecular Probes). Negative controls were performed without the ®rst antibodies. DNA was counterstained with the DNA¯uorochrome 4',6'diamedino-2-fenylindole (DAPI). Cells were visualized in a Nikon Eclipse E300 uorescent microscope equipped with digital camera. Images were prepared with Adobe Photoshop.
Adenosine nucleotide modulated binding assay
For adenosine nucleotide modulation studies, GST-BRCA1(1 ± 625) bound glutathione beads were ®rst washed and equilibrated with Binding Buer [50 mM HEPES pH 7.5, 100 mM NaCl, 0.25% NP-40, 1 mM DTT, 0.5% BSA, and 10 mM of MgCl 2 ] and speci®ed adenosine nucleotide. The beads were then incubated with 3.9 nM of puri®ed hMSH2-hMSH6 (Gradia et al., 1997) pre-equilibrated with speci®ed adenosine nucleotide in Binding Buer. Proteins bound to GST-BRCA1(1 ± 625) were washed once in binding buer containing speci®ed adenosine nucleotide, precipitated by centrifugation, separated by SDS ± PAGE and detected by Western analysis using antibodies speci®c for hMSH2 and hMSH6 (Transduction Laboratories, Los Angeles, CA, USA). Individual adenosine nucleotide modulation experiments were reproduced a minimum of four times with equivalent results.
Abbreviations MMR, mismatch repair; TCR, transcription-coupled DNA damage repair
